Toxicology Letters, 64/65 (1992) 789–794
© 1992 Elsevier Science Publishers B.V.

AUTHOR INDEX VOL. 64/65 (1992)

Adamson, G.M., see Harman, A.W., 581
Aldridge, W.N., The Toxic Oil Syndrome (TOS, 1981): from the disease towards a toxicological understanding of its chemical aetiology and mechanism, 59
Alexandrov, K., see Bartsch, H., 477
Alleva, E., see Bignami, G., 231
Ansell, G., Epidemiology of adverse reactions to intravascular iodinated contrast media, 717
Antunes, E., see Corrado, A.P., 739
Anwar, W.A., see Wild, C.P., 455
Arens, H.J., see Oesch, F., 643
Ashby, J., Prediction of non-genotoxic carcinogenesis, 605
Aust, S.D., see Shah, M.M., 493

Bagetta, G. and Nisticò, G., Glutamate transmission is involved in the mechanisms of neuronal degeneration produced by intrahippocampal tetanus toxin in rats, 447
Ballejo, G., see Corrado, A.P., 739
Barbolt, T.A., see Cornacoff, J.B., 299
Barr, D.P., see Shah, M.M., 493
Bartsch, H., Castegnaro, M., Rojas, M., Camus, A.-M., Alexandrov, K. and Lang, M., Expression of pulmonary cytochrome P4501A1 and carcinogen DNA adduct formation in high risk subjects for tobacco-related lung cancer, 477
Bass, R., see Hodel, C., 149
Bass, R., Kleeberg, U., Schröder, H. and Scheibner, E., Current guidelines for the preclinical safety assessment of therapeutic proteins, 339
Baud, F.J., Richter, F., Julien, H. and Bismuth, C., Pre-hospital strategy for therapeutic intervention of fire victims, 273
Becking, G.C., Methodology in neurotoxicology — activities within the World Health Organization and International Programme on Chemical Safety, 203
Beere, H.M., see Hickman, J.A., 553
Bernard, A., see Lauwerys, R., 33
Bertolero, F., see Mazué, G., 329
Bertolotti, M., see Trenti, T., 757
Bignami, G., Laviola, G., Alleva, E., Cagiano, R., Lacomba, C. and Cuomo, V., Developmental aspects of neurobehavioural toxicity, 231
Bismuth, C., see Baud, F.J., 273
Boobis, A.R., Molecular basis for differences in susceptibility to toxicants: introduction, 109
Boobis, A.R., see Davies, D.S., 575
Borm, P.J.A., Schins, R., Janssen, Y.M.W. and Lenaerts, L., Molecular basis for differences in susceptibility to coal workers' pneumoconiosis, 767
Botham, P.A., Classification of chemicals as sensitisers based on new test methods, 165
Brughera, M., see Mazué, G., 329
Bucher, K.D., see Hein, D.W., 123
Bursch, W., see Schulte-Hermann, R., 569
Bus, J.S. and Reitz, R.H., Dose-dependent metabolism and dose setting in chronic studies, 669

Cagiano, R., see Bignami, G., 231
Calamari, D., Advances in prediction of exposure for organic chemicals, 519
Caldwell, J., Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism, 651
Calvin, G., New approaches to the assessment of eye and skin irritation, 157
Camus, A.-M., see Bartsch, H., 477
Capen, C.C., Pathophysiology of chemical injury of the thyroid gland, 381
Cardenas, A., see Lauwerys, R., 33
Carminati, P., see Mazué, G., 329
Castegnaro, M., see Bartsch, H., 477

Castellana, C.N., see Trenti, T., 757
Cavagnaro, J.A., see Hayes, T.J., 291
Ceccarelli, D., see Trenti, T., 751
Charles, S.J. and Powell, C.J., Rapidly developing cocaine-induced peripheral portal liver damage, 729
Christensen, H.B., see Juul, P., 85
Chung, N., see Shah, M.M., 493
Civeira, E.,see Nogué, S., 725
Claude, J.-R., Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnologically-produced drugs: some examples, 349
Comment, C.E., see Luster, M.I., 71
Cornacoff, J.B., Gossett, K.A., Barbolt, T.A. and Dean, J.H., Preclinical evaluation of recombinant human interleukin-4, 299
Corrado, A.P., Ballejo, G., Antunes, E. and de Nucci, G., Mechanism of pain induced by radiocontrast media, 739
Corsini, A., see Soma, M.R., 1
Costa, L.G., see Manzo, L., 677
Creppy, E.-E., see Kretz, O., 763
Crossland, N.O., Hazard assessment in freshwater ecosystems, 511
Cuomo, V., see Bignami, G., 231

D'Hooge, R., Pei, Y.-Q., Marescau, B. and De Deyn, P.P., Behavioral toxicity of guanidinosuccinic acid in adult and young mice, 773
Davies, D.S., Fawthrop, D.J., Nasseri-Sina, P., Wilson, J.W., Hardwick, S.J. and Boobis, A.R., Paracetamol toxicity and its prevention by cytoprotection with iloprost, 575
De Deyn, P.P., see D'Hooge, R., 773
de Groot, H., see Sies, H., 547
de Nucci, G., see Corrado, A.P., 739
Dean, J.H., see Cornacoff, J.B., 299
Dearman, R.J., see Kimber, I., 79
del Carmine, R., see Navarra, P., 745
Descotes, J., The popliteal lymph node assay: a tool for studying the mechanisms of drug-induced autoimmune disorders, 101
Deshmukh, P.B., Three-generation reproductive studies of a synthetic pyrethroid — cyhalothrin, 779
Dirheimer, G., see Kretz, O., 763
Doll, M.A., see Hein, D.W., 123
Donelli, G. and Fiorentini, C., Cell injury and death caused by bacterial protein toxins, 695
Dourson, M.L., see Lu, F.C., 783
DuBow, M.S., see Guzzo, J., 687
Dypbukt, J.M., see Nicotera, P., 563

Ehrenberg, L. and Törnqvist, M., Use of biomarkers in epidemiology: quantitative aspects, 485
Eichelbaum, M., Kroemer, H.K. and Mikus, G., Genetically determined differences in drug metabolism as a risk factor in drug toxicity, 115
Ericson, L.E. and Nilsson, M., Structural and functional aspects of the thyroid follicular epithelium, 365

Fawthrop, D.J., see Davies, D.S., 575
Feng, Y., see Hein, D.W., 123
Ferguson, R.J., see Hein, D.W., 123
Ferrari, A., see Trenti, T., 757
Ferrer, A., see Nogué, S., 725
Fiorentini, C., see Donelli, G., 695
Frantík, E. and Horváth, M., Integration of behavioral and neurophysiological approaches in neurotoxicology, 225
Frey, J.M., see Narahashi, T., 429
Friedberg, T., see Oesch, F., 643
Fritsch, G., see Oberhammer, F., 701
Froschl, G., see Oberhammer, F., 701
Furman, E.J., see Hein, D.W., 123

Gale, K., Role of GABA in the genesis of chemoconvulsant seizures, 417
Gallesi, D., see Trenti, T., 751
Garofano, L., see Mazué, G., 329
Germolec, D.R., see Luster, M.I., 71
Ginsburg, K.S., see Narahashi, T., 429
Glatt, H.R., see Oesch, F., 643
Gossett, K.A., see Cornacoff, J.B., 299
Grandjean, P., Individual susceptibility to toxicity, 43
Gray, K., see Hein, D.W., 123
Green, J.D. and Terrell, T.G., Utilization of homologous proteins to evaluate the safety of recombinant human proteins — case study: recombinant human interferon-gamma (rhIFN-γ), 321
Green, S., Tugwood, J.D. and Issemann, I., The molecular mechanism of peroxisome

proliferator action: a model for species differences and mechanistic risk assessment, 131
Guzelian, P.S., The clinical toxicology of Chlordecone as an example of toxicological risk assessment for man, 589
Guzzo, A., see Guzzo, J., 687
Guzzo, J., Guzzo, A. and DuBow, M.S., Characterization of the effects of aluminum on luciferase biosensors for the detection of ecotoxicity, 687

Hansen, J.J., see Krogsgaard-Larsen, P., 409
Hansson, J., Inherited defects in DNA repair and susceptibility to DNA-damaging agents, 141
Hardwick, S.J., see Davies, D.S., 575
Harman, A.W., Adamson, G.M. and Shaw, S.G., Protection from oxidative damage in mouse liver cells, 581
Hasegawa, R., see Ito, N., 613
Hayes, T.J. and Cavagnaro, J.A., Progress and challenges in the preclinical assessment of cytokines, 291
Hein, D.W., Rustan, T.D., Doll, M.A., Bucher, K.D., Ferguson, R.J., Feng, Y., Furman, E.J. and Gray, K., Acetyltransferases and susceptibility to chemicals, 123
Henschler, D., Evaluation of adverse effects in the standard-setting process, 53
Hiasa, Y., Kitahori, Y., Konishi, N. and Ohshima, M., Chemical carcinogenesis in the thyroid gland, 389
Hickman, J.A., Beere, H.M., Wood, A.C., Waters, C.M. and Parmar, R., Mechanisms of cytotoxicity caused by antitumour drugs, 553
Hirvonen, M.-R., see Savolainen, K.M., 437
Hodel, C. and Bass, R., Are newer scientific concepts in regulatory toxicology used timely and appropriately?, 149
Horváth, M., see Frantík, E., 225
Hougen, H.P., see Juul, P., 85

Ikeda, M., Public health problems of organic solvents, 191
Imaida, K., see Ito, N., 613
Issemann, I., see Green, S., 131
Ito, N., Hasegawa, R., Imaida, K., Masui, T., Takahashi, S. and Shirai, T., Pathological markers for non-genotoxic agent-associated carcinogenesis, 613

Janssen, Y.M.W., see Borm, P.J.A., 767
Julien, H., see Baud, F.J., 273
Juul†, P., Christensen, H.B., Hougen, H.P., Svendsen, O., Thygesen, P. and Rygaard, J., Athymic experimental animals in pharmaco-immunological research, 85

Kaderlik, R.K., Lin, D.-X., Lang, N.P. and Kadlubar, F.F., Advantages and limitations of laboratory methods for measurement of carcinogen-DNA adducts for epidemiological studies, 469
Kadlubar, F.F., see Kaderlik, R.K., 469
Kammüller, M., see Ryffel, B., 311
Kato, R. and Yamazoe, Y., Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity, 661
Kimber, I. and Dearman, R.J., The mechanisms and evaluation of chemically induced allergy, 79
Kitahori, Y., see Hiasa, Y., 389
Kleeberg, U., see Bass, R., 339
Konishi, N., see Hiasa, Y., 389
Kramers, P.G.N. and Roelfzema, H., Classification of chemicals for carcinogenic and mutagenic properties, 173
Kraupp-Grasl, B., see Schulte-Hermann, R., 569
Kretz, O., Reinbolt, J., Creppy, E.-E. and Dirheimer, G., Properties of bolesatine, a translational inhibitor from *Boletus satanas* Lenz. Amino-terminal sequence determination and inhibition of rat mitochondrial protein synthesis, 763
Kroemer, H.K., see Eichelbaum, M., 115
Krogsgaard-Larsen, P. and Hansen, J.J., Naturally-occurring excitatory amino acids as neurotoxins and leads in drug design, 409
Kulling, P., Hospital treatment of victims exposed to combustion products, 283

Lacomba, C., see Bignami, G., 231
Lang, N.P., see Kaderlik, R.K., 469
Lang, M., see Bartsch, H., 477
Lauwerys, R., Bernard, A. and Cardenas, A., Monitoring of early nephrotoxic effects of industrial chemicals, 33

Laviola, G., see Bignami, G., 231
Lenaerts, L., see Borm, P.J.A., 767
Levin, B.C., The development of a new small-scale smoke toxicity test method and its comparison with real-scale fire tests, 257
Lilienthal, H., see Winneke, G., 239
Lin, D.-X., see Kaderlik, R.K., 469
Lu, F.C. and Dourson, M.L., Safety/risk assessment of pesticides: principles, procedures and examples, 783
Luebeck, E.G., see Moolgavkar, S.H., 631
Lundgren, A., Environmental hazard classification of chemicals, 535
Luster, M.I., Pait, D.G., Portier, C., Rosenthal, G.J., Germolec, D.R., Comment, C.E., Munson, A.E., White, K. and Pollock, P., Qualitative and quantitative experimental models to aid in risk assessment for immunotoxicology, 71

MacPhail, R.C., Principles of identifying and characterizing neurotoxicity, 209
MacPhail, R.C., see Moser, V.C., 217
Malacarne, D., see Parodi, S., 621
Manzo, L., Costa, L.G., Tonini, M., Minoia, C. and Sabbioni, E., Metabolic studies as a basis for the interpretation of metal toxicity, 677
Manzo, L., see Nicotera, P., 563
Marescau, B., see D'Hooge, R., 773
Marruecos, L., see Nogué, S., 725
Martire, M., see Navarra, P., 745
Masini, A., see Trenti, T., 751
Masui, T., see Ito, N., 613
Mazué, G., Bertolero, F., Garofano, L., Brughera, M. and Carminati, P., Experience with the preclinical assessment of basic fibroblast growth factor (bFGF), 329
McCabe Jr., M.J., see Orrenius, S., 357
McGregor, D.B., Chemicals classified by IARC: an investigation of some of their toxicological characteristics, 637
McLain, R.M., Thyroid gland neoplasia: non-genotoxic mechanisms, 397
Mesnil, M., see Yamasaki, H., 597
Mikus, G., 115
Minoia, C., see Manzo, L., 677
Monteís, J., see Nogué, S., 725
Montesano, R., see Wild, C.P., 455
Moolgavkar, S.H. and Luebeck, E.G., Risk assessment of non-genotoxic carcinogens, 631
Morisetti, A., see Rosati, G., 705
Moser, V.C. and MacPhail, R.C., International validation of a neurobehavioral screening battery: the IPCS/WHO collaborative study, 217
Munson, A.E., see Luster, M.I., 71
Myers, L., see Ryffel, B., 311

Nakazawa, H., see Yamasaki, H., 597
Narahashi, T., Frey, J.M., Ginsburg, K.S. and Roy, M.L., Sodium and GABA-activated channels as the targets of pyrethroids and cyclodienes, 429
Nasseri-Sina, P., see Davies, D.S., 575
Navarra, P., Martire, M., del Carmine, R., Pozzoli, G. and Preziosi, P., A dual effect of some 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon, 745
Nicotera, P., see Orrenius, S., 357
Nicotera, P., Dypbukt, J.M., Rossi, A.D., Manzo, L. and Orrenius, S., Thiol modification and cell signalling in chemical toxicity, 563
Nieboer, E., Rossetto, F.E. and Turnbull, J.D., Molecular biology approaches to biological monitoring of genotoxic substances, 25
Nilsson, U., see Skerfving, S., 17
Nilsson, M., see Ericson, L.E., 365
Nisticò, G., see Bagetta, G., 447
Nogué, S., Marruecos, L., Nolla, J., Monteís, J., Ferrer, A. and Civeira, E., The profile evolution of acute severe poisoning in Spain, 725
Nolla, J., see Nogué, S., 725

Oberhammer, F., see Schulte-Hermann, R., 569
Oberhammer, F., Fritsch, G., Pavelka, M., Froschl, G., Tiefenbacher, R., Purchio, T. and Schulte-Hermann, R., Induction of apoptosis in cultured hepatocytes and in the regressing liver by transforming growth factor-β1 occurs without activation of an endonuclease, 701
Oesch-Bartlomowicz, B., see Oesch, F., 643
Oesch, F., Oesch-Bartlomowicz, B., Arens, H.J., Friedberg, T., Utesch, D., Glatt,

H.R. and Platt, K.L., Molecular and cellular basis for adequate metabolic design of genotoxicity studies, 643
Ohshima, M., see Hiasa, Y., 389
Orrenius, S., see Nicotera, P., 563
Orrenius, S., McCabe Jr., M.J. and Nicotera, P., Ca2+-dependent mechanisms of cytotoxicity and programmed cell death, 357

Pait, D.G., see Luster, M.I., 71
Paoletti R., see Soma, M.R., 1
Parmar, R., see Hickman, J.A., 553
Parodi, S., Malacarne, D. and Taningher, M., Non-genotoxic factors in the carcinogenetic process: problems of detection and hazard evaluation, 621
Pauluhn, J., Modeling of toxicological effects of fire effluents: prediction of toxicity and evaluation of animal model, 265
Pavelka, M., see Oberhammer, F., 701
Pei, Y.-Q., see D'Hooge, R., 773
Pini, L.A., see Trenti, T., 757
Platt, K.L., see Oesch, F., 643
Poels, C.L.M. and Veerkamp, W., Hazard assessment of chemical contaminants in soil, 503
Pollock, P., see Luster, M.I., 71
Portier, C., see Luster, M.I., 71
Powell, C.J., see Charles, S.J., 729
Pozzoli, G., see Navarra, P., 745
Preziosi, P., see Navarra, P., 745
Purchio, T., see Oberhammer, F., 701
Purser, D.A., The evolution of toxic effluents in fires and the assessment of toxic hazard, 247

Reinbolt, J., see Kretz, O., 763
Reitz, R.H., see Bus, J.S., 669
Richter, F., see Baud, F.J., 273
Robison, R., see Ryffel, B., 311
Roelfzema, H., 173
Rojas, M., see Bartsch, H., 477
Rosati, G., Morisetti, A. and Tirone, P., Toxicity in animals and safety in humans: the predictive value of animal studies, 705
Rosenthal, G.J., see Luster, M.I., 71
Rossetto, F.E., see Nieboer, E., 25
Rossi, A.D., see Nicotera, P., 563
Roy, M.L., see Narahashi, T., 429
Rustan, T.D., see Hein, D.W., 123
Ryffel, B., Kammüller, M., Robison, R. and Myers, L., Pathology induced by Interleukin-6, 311
Rygaard, J., see Juul, P., 85

Sabbioni, E., see Manzo, L., 677
Savolainen, K.M. and Hirvonen, M.-R., Second messengers in cholinergic-induced convulsions and neuronal injury, 437
Scheibner, E., see Bass, R., 339
Schins, R., see Borm, P.J.A., 767
Schröder, H., see Bass, R., 339
Schulte-Hermann, R., see Oberhammer, F., 701
Schulte-Hermann, R., Bursch, W., Krauppp-Grasl, B., Oberhammer, F. and Wagner, A., Programmed cell death and its protective role with particular reference to apoptosis, 569
Shah, M.M., Barr, D.P., Chung, N. and Aust, S.D., Use of white rot fungi in the degradation of environmental chemicals, 493
Shaw, S.G., see Harman, A.W., 581
Shirai, T., see Ito, N., 613
Shrestha, S.M., see Wild, C.P., 455
Sies, H. and de Groot, H., Role of reactive oxygen species in cell toxicity, 547
Skerfving, S. and Nilsson, U., Assessment of accumulated body burden of metals, 17
Soma, M.R., Corsini, A. and Paoletti R., Cholesterol and mevalonic acid modulation in cell metabolism and multiplication, 1
Sternieri, E., see Trenti, T., 757
Sternieri, E., see Trenti, T., 751
Sullivan, F.M., The European Community classification of chemicals for reproductive toxicity, 183
Svendsen, O., see Juul, P., 85

Takahashi, S., see Ito, N., 613
Taningher, M., see Parodi, S., 621
Terrell, T.G., see Green, J.D., 321
Thygesen, P., see Juul, P., 85
Tiefenbacher, R., see Oberhammer, F., 701
Tirone, P., see Rosati, G., 705
Tonini, M., see Manzo, L., 677
Törnqvist, M., see Ehrenberg, L., 485
Trenti, T., Bertolotti, M., Castellana, C.N., Ferrari, A., Pini, L.A. and Sternieri, E., Plasma glutathione level in paracetamol

daily abuser patients. Changes in plasma cysteine and thiol groups after reduced glutathione administration, 757
Trenti, T., Sternieri, E., Ceccarelli, D., Gallesi, D. and Masini, A., Production of lipid hydroperoxides and depletion of reduced glutathione in liver mitochondria after acute ethanol administration to rats, 751
Tugwood, J.D., see Green, S., 131
Turnbull, J.D., see Nieboer, E., 25

Udaka, K., Cellular and humoral mechanisms of immunotoxicological tissue manifestations induced by immunotoxic drugs, 93
Utesch, D., see Oesch, F., 643

Veerkamp, W., see Poels, C.L.M., 503
Vineis, P., The use of biomarkers in epidemiology: the example of bladder cancer, 463

Wagner, A., see Schulte-Hermann, R., 569
Walker, C.H., Biochemical responses as indicators of toxic effects of chemicals in ecosystems, 527
Waters, C.M., see Hickman, J.A., 553
White, K., see Luster, M.I., 71
Wild, C.P., Shrestha, S.M., Anwar, W.A. and Montesano, R., Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in The Gambia and Thailand, 455
Williams, E.D., Cell proliferation and thyroid neoplasia, 375
Wilson, J.W., see Davies, D.S., 575
Winneke, G. and Lilienthal, H., Extrapolation from animals to humans: scientific and regulatory aspects, 239
Wood, A.C., see Hickman, J.A., 553

Yamasaki, H., Mesnil, M. and Nakazawa, H., Interaction and distinction of genotoxic and non-genotoxic events in carcinogenesis, 597
Yamazoe, Y., see Kato, R., 661

Toxicology Letters, 64/65 (1992) 795–800
© 1992 Elsevier Science Publishers B.V.

SUBJECT INDEX VOL. 64/65 (1992)

Acetylcholine, 417
N-Acetylation, 123
O-Acetylation, 123
N-Acetyltransferases, 43
Acrylamide, 217
Acute poisoning, 725
Acyl CoA oxidase, 131
Adducts, 485
ADI, 783
Adverse effects, 53
Adverse reactions, 705, 717
Aflatoxin, 455
Age, 437
Ah receptor, 109
Altered foci, 631
Aluminum, 687
3-Aminophenyl-1,2-propane diol, 59
Anilides, 49
Antidotes, 273
Antioxidant depletion, 547
Antitumour drugs, 553
Apoptosis, 357, 553, 563, 569, 631, 701
Arsenic, 677
Arsenobetaine, 677
Arylamine metabolism, 463
Arylamines, 123
AS52 Chinese hamster ovary cells, 25
Ascorbic acid, 547
Asphyxiation, 247
Ataxia-telangiectasia, 141
Autoimmunity, 101

Barrier function, 365
Basic fibroblast growth factor (bFGF), 329
Behavioral development, 231
Behavioral teratology, 239
Behavioral toxicity, 225
Bicuculline, 417
Biochemical epidemiology, 455
Biochemical responses, 527
Biological markers, 767
Biological monitoring, 17, 25
Biomarkers, 25, 43, 485, 527
Biomonitoring, 677
Biosensors, 687
Biotechnologically produced drugs, 349
Biotechnology, 291, 339, 349
Bladder carcinogenesis, 463
Bleb formation, 357
Bloom's syndrome, 141
Boletus satanas, 763
Bone hyperostosis, 329
Bone, 17
Bradykinin, 739
Brodifacoum, 527

c-*myc* gene, 553
Ca^{2+}, 563
Ca^{2+}-dependent endonucleases, 357
Cadmium, 17, 25, 33
Calcium, 357
Calmodulin, 357
Cancer epidemiology, 469
Carbamate insecticides, 527
Carbon monoxide, 247
Carboxylesterases, 527
Carcinogen DNA adducts, 477
Carcinogenesis, 569, 631
Carcinogenic chemicals, 173
Carcinogens, 637
Carotenoids, 547
Cell death, 357, 569
Cell division, 631
Cell proliferation, 1, 375
Cell transformation, 597
CGP37849, 447
Chemical carcinogenesis, 469
Chemical injury, 203
Chemical structure, 605
Chemiluminescence, 547
Children, 43
Chlordecone, 589
Cholinergic-induced convulsions, 437
Cholinesterases, 527
Chromanoxyl radical, 547
Chromatin fragmentation, 357

Chromium, 677
Cigarette smoking, 463, 477
Cinnamyl anthranilate, 651
Cisplatin, 745
Classification of carcinogens and mutagens, 173
Classification criteria, 535
Classification and labelling, 535
Clinical surveys, 705
Clostridium difficile toxin A, 695
Cocaine, 729
Cockayne's syndrome, 141
Cofactors, 643
Cognitive impairment, 239
Colorectal cancer, 123
Combustion products, 293
Compound-specific DNA lesions, 25
Congenic hamsters, 123
Contact allergy, 79
Contaminated soil, 503
Contrast media, 717
Controlled gene expression, 339
Convulsant seizures, 417
Convulsions, 437
Council Directive 67/548/EEC, 183
Cyhalothrin, 779
Cynomolgus monkeys, 299, 321, 329
CYP1A-related enzymes, 477
CYP1A1, 109
CYP2C11, 611
CYP2D6, 109
CYP3A2, 611
Cysteine, 757
Cytochrome P450, 43
Cytokines, 79, 291
Cytoprotection, 575
Cytoskeleton, 695
Cytotoxicity, 547, 553, 695

Dangerous Substances Directive, 183
DDT, 783
p,p'-DDT, 217
Demethylarsinic acid, 677
Demethylation process, 677
Demeton-*S*-methyl, 527
Developmental change, 661
Developmental neurotoxicology, 239
Developmental toxicity, 183
Diabetes, 611
Diabetes mellitus, 85
Dibutyltin, 677
Dieldrin, 429
Differentiation, 631
7,12-Dimethylbenz[*a*]anthracene, 597
DIN 53436 test method, 265
Di[2-ethylhexyl]adipate, 621
p-Dihydroxyboryl phenylalanine (BPA), 677
DNA adduct formation, 527
DNA adducts, 469
DNA-ladders, 569
DNA methylation, 597
DNA repair, 141
Domoic acid, 409
Dose level, 605
Drug allergy, 93
Drug design, 409
Drug development, 291, 321
Drug hypersensitivity animal model, 93
Drug metabolism, 115
Drug toxicity, 115
Dypyrone, 621

E-cadherin, 365
Ebselen, 547, 581
Ecogenetics, 43
Ecosystems, 527
Ecotoxicology, 519
Emesis, 745
Endonuclease, 553, 701
Endonuclease activation, 357
Environmental compounds, 589
Environmental chemicals, 493, 519, 527
Environmental hazard labelling, 535
Eosinophilia, 59
Eosinophilia Myalgia Syndrome (EMS), 59
Epidemiology, 43, 463, 485
Epilepsy, 773
Epoxide hydrolase, 643
Erythrosine (FD&C Red No. 3), 381
Escherichia coli CNF1, 695
Ethanol, 751
Ethics, 43
o-Ethoxybenzamide, 621
Excitatory amino acids, 409
Expected environmental concentrations, 511
Exposure assessment, 519
Exposure markers, 455
Eye irritation, 157

Fanconi's anemia, 141
Fasting, 611
Fertility, 183
Fire, 247

Fire effluents, 265
Fire gases, 293
Fire hazard, 257
Fire victims, 273
Flocoumafen, 527
Freshwater ecosystems, 511
Functional effects, 225
Functional observational battery, 217

GABA, 417
GABA receptor channel, 429
Gamma-vinyl GABA, 417
Gas poisoning, 283
Gene deletions, 25
Gene fusions, 687
Genetic monitoring and screening, 25
Genetic polymorphism, 43, 109
Genetic testing, 25
Genomic instability, 597
Genotoxic carcinogens, 597, 605, 613, 621
Genotoxicity, 25
Glioma cells, 1
Glomerulonephritis, 311
Glutamate, 417
(*S*)-Glutamic acid, 409
Glutathione, 547, 677
Glutathione S-transferase placental form (GST-P), 569, 613, 631
Glutathione transferases, 643
Glycophorin A (GPA) assay, 25
Goitrogen, 397
Goitrogenic chemicals, 381
Gold, 677
Graft-versus-host-like mechanism, 101
Growth factor, 563
Growth hormone, 611
GSSG, 581
Guanethidine, 85
Guanidino compounds, 773
Guanidinosuccinic acid, 773

Harmonization, 535
Hazard, 247
Hazard assessment, 503, 511, 519
Health, definition of, 53
Heat shock proteins, 553
Hepatic microsomal induction, 381
Hepatitis B virus, 455
Hepatocarcinogenesis, 631
Hepatocellular carcinoma, 455
Hepatotoxicity, 729
Hereditary dysplastic nevus syndrome, 141
Hippocampal damage, 447
Histological lesions in the glomeruli, 329
HMGCoA reductase inhibitors, 1
Hormonal imbalance, 397
Hormonal regulation, 611
HPRT assay, 25
Human DNA repair genes, 141
Human exposure to soil pollutants model, 503
Human genome project, 25
Human health, 503
Human leukocyte antigen A (HLA-A) assay, 25
Human-specific metabolites, 651
Hydrogen cyanide, 247
Hydroxyl radicals, 493
Hypersusceptibility, 43
Hypolipidemic drugs, 131
Hypoxia-reoxygenation, 547

Ibotenic acid, 409
Iloprost, 575
Immunoassays, 469
Immunogenicity, 311
Immunotoxic cellular response, 93
Immunotoxic humoral response, 93
Immunotoxicology, 71, 93
Indicators of exposure, 25
Indices of exposure, 25
Indirect hazard, 225
Individual susceptibility, 43
Induction, 109
Inhalation injury, 293
Inhibitors of 5′-deiodinase, 381
Initiation, 389
Inositol phosphates, 437
Insulin-like growth factor 1, 375
Intensive care units, 725
Interferon-gamma, 321
Interleukin-6, 311
Intoxication, 725
Intraspecific variability, 43
Iodinated contrast media, 705
Ionic, 717
IPCS, 217
Isoniazid, 417

Jaundice, 43

Kidney, 17, 33
Kupffer cells, 547

Labelling, 173
Labelling of dangerous substances, 183
Lead, 17, 239, 677
Lead acetate, 217
Lead compounds, 25
Lead exposure, 43
Lead neutoxicity, 43
Lethal dose 50, 637
Lignin, 493
Lignin peroxidases, 493
Lindane, 429
Lipid hydroperoxides, 751
Liver cancer, 131
Liver cirrhosis, 43
Liver necrosis, 729
LOAEL, 239
Luciferase, 687
Lung cancer, 477
Lung inflammation, 247

Margin of safety, 705
Markers of early biological response, 25
Maximum tolerated dose, 669
Mechanisms of action, 209
Mechanisms of sensitisation, 165
Mercury, 677
Metabolic models for humans, 651
Metabolic phenotypes, 477
Metabolic polymorphism, 463
Metals, 563
Metallothionein, 25
Metallothionein induction, 25
Methodology, 203
N,N'-Methylene bisacrylamide, 217
Methylene chloride, 669
Methylmercury, 677
Microsomal enzyme inducers, 397
Mitochondria, 763
MK801, 447
Modeling of combustion toxicity, 265
Modelling, 247
Molecular biology, 25
Molecular epidemiology, 25, 455
Mouse hepatocyte, 581
Multiplicative model, 495
Multistage carcinogenesis, 597
Mushroom toxin, 763
Mutagenesis, 637
Mutagenic chemicals, 173
Mutation, 631
Mutins, 339
Myalgia, 59

N-bis(2-hydroxypropyl)nitrosamine, 389
N-Gas Model, 257, 265
NADPH oxidase, 547
NAT2, 109
Neoplasm, 389
Nephrotoxicity, 33
Neurobehaviour, 203
Neuronal injury, 437
Neurotoxicity, 225
Neurotoxicology, 203, 209
Neurotoxins, 43
New test methods, 165
Nickel compounds, 25
Nitric oxide, 547, 739
L-Nitroarginine methyl esther, 739
S-Nitrosocysteine, 739
NO synthase, 547
No-effect level, 33
No-observed effect concentrations, 511
NOAEL, 239
Non-genotoxic carcinogens, 397, 597, 605, 613, 621
Non-ionic, 717
Normochromic normocytic anemia, 329
Nuclear hormone receptor, 131
Nude rats, 85
Nude mice, 85

Occupational exposure limits, 53
β-ODAP, 409
OECD guidelines, 165
Oncogene proteins, 25
Oncogenes, 25, 375
Organic boron derivatives, 677
Organic solvents, 191
Organochlorine pesticides, 589
Organomercurials, 677
Organophosphorus, 527
Organotin compounds, 677
Osteoporosis, 43
Oxidative stress, 563, 581
Oxygen deprivation, 273

Paracetamol, 575, 581, 757
Parathion, 217
Parental care, 231
PCBs, 239
Peroxisome proliferator, 131
Peroxynitrite, 547
Pesticides, 783
Pharmacokinetics, 669
Phenobarbital, 397

o-Phenylphenol, 669
Phlebotomy, 43
Phospholipases, 357
Phosphorylation, 643
Picrotoxin, 417
Pneumoconiosis, 767
Point mutations, 25
Popliteal lymph node assay, 101
Post-flashover, 257
Preclinical safety, 299
Predictive testing, 79
Prenatal benzodiazepines, 231
Prenatal haloperidol, 231
Promotion, 389
Proteases, 357
Protein synthesis inhibition, 763
Proteinous toxin, 763
Proto-oncogenes, 25, 553
Public health, 191
Pyrethroids, 429, 779

Quantitative analysis, 71

Radiant heat, 257
Rat liver medium-term bioassay, 613
Rat liver mitochondria, 751
Reactive metabolites, 643
Reactive oxygen species, 547
Real-scale fire tests, 257
5-HT3 Receptor agonists, 745
5-HT3 Receptor antagonists, 745
Recombinant gene technology, 339
Recombinant human interleukin-4, 299
Recombinant human protein, 321
Recombinant murine protein, 321
Reduced glutathione, 751, 757
Regulations, 291
Regulatory toxicology, 149
Renal markers, 33
Reproduction, 779
Reserve capacity, 43
Respiratory allergy, 79
Respiratory sensitisation, 165
RfD, 783
RFLP, 109
rhuIL-4, 299
Risk assessment, 71, 149, 239, 485, 519, 527, 589, 597, 783
Ruthenium complexes, 677
Ruthenium red, 739

Safety assessment, 321, 339, 589
Safety evaluations, 291
Safety margin, 705
Saturation, 669
Schaffer collaterals lesion, 447
Screening, 209
Secondary mechanisms of thyroid oncogenesis, 381
Selenium, 677
Sensory initiation, 53
Sex, 437
Sex-specific cytochrome P450, 661
Skin irritation, 157
Skin sensitisation, 165
Smoke inhalation, 273
Smoke toxicity tests, 257
Smooth muscle cells, 1
Sodium channel, 429
Solvents, 225
Somatic gene mutations, identifying, 25
Somatic mutation, 631
Species differences, 397, 651
Species specificity, 321
Sprague Dawley rats, 329
Standard-setting, 53
Streptozotocin, 85
Subcutaneous injections, 299
Sulfonamides, 397
Superoxide, 493
Suppressor genes, 25
Susceptibility to environmental agents, 25
Sympathectomy, 85

T helper cells, 79
TCCD, 357
Test procedures, 149
Testing safety, 149
Tetanus toxin, 447
12-*O*-Tetradecanoylphorbol 13-acetate, 597
TGF-β1, 701
Thallium, 677
Therapeutic proteins, 339
Thioacetamide, 621
Thiol groups, 757
[^{3}H]Thymidine incorporation, 365
Thymocytes, 357
Thyroid, 389
Thyroid cancer, 375
Thyroid gland neoplasia, 397
Thyroid gland peroxidase, 397
Thyroid hormone metabolism, 397
Thyroid hormone synthesis and release, 365
Thyroid stimulating hormones, 397

Thyroid tumors, 381, 397
Thyroxine, 397
Tiered testing, 209
Tin, 677
TNFα, 767
α-Tocopherol, 547
α-Tocopheroxyl radical, 547
Toluene, 217
Toxic for reproduction, 183
Toxicity testing, 149
Trialkyltin, 677
Tributyltin, 357, 677
Triethyl tin, 217
Trimethyltin, 677
p53 Tumour suppressor gene, 455
Type III procollagen, 767
Ultrasonic vocalizations, 231
Uremia, 773
Urinary bladder cancer, 123

Vanadium, 677
Vinyl chloride, 669
Vitamin K, 527
Vulnerability, 43

White rot fungi, 493

X-ray fluorescence, 17
Xenobiotic metabolism, 651
Xeroderma pigmentosum, 141